Attovia Therapeutics prices IPO at $17 per share on Nasdaq
Attovia Therapeutics (Nasdaq: ATTO) priced its IPO at $17.00 per share, selling 17.0 million shares for expected gross proceeds of about $289.0 million, with a 30-day option for up to 2.55 million more shares. The stock is set to start trading Aug. 5, 2026, under ATTO. Joint bookrunners include Morgan Stanley, Leerink, Citigroup, and RBC.
How this was made
The 30-second read
Why it matters
The immediate market impact is the transition from private financing to public trading, with the priced IPO terms determining initial supply and investor expectations.
Market read
Traders can position for IPO-specific volatility and liquidity effects as ATTO starts trading on Aug 5, 2026.
What to watch
No details are provided on expected cash runway, trial readouts, or institutional allocation, which are often the real drivers of post-IPO drift.
Background
Attovia is a clinical-stage biopharmaceutical company developing anti-IL-31 and other immune-mediated disease candidates (ATTO-1310, ATTO-2306, ATTO-1091).
Ticker impact
Attovia Therapeutics priced its IPO at $17 per share on Nasdaq, with $289.0M gross proceeds and a 30-day underwriter option.
Likely elevated opening volatility and price discovery around the $17 IPO price as the stock begins trading Aug 5.
The article discloses concrete IPO terms (price, shares, proceeds, start date) but provides no valuation or demand metrics beyond the upsized offering.
Market effects
Adds a new clinical-stage immune-mediated disease biotech listing, which can marginally affect sentiment toward small-cap biotech IPO appetite.
Primarily US-focused via Nasdaq listing and IPO flow.
Limited, as the disclosure is company-specific and not a cross-border policy or supply-chain event.
Counterpoint
IPO pricing alone does not confirm strong demand; first-day performance can disappoint if allocation is weak or valuation is rich versus peers.
Key entities
- companyAttovia Therapeutics, Inc.
Clinical-stage biopharmaceutical company that priced its Nasdaq IPO at $17 per share.
- pipeline_assetATTO-1310
Lead candidate, an anti-IL-31 therapeutic in clinical development for chronic pruritic diseases.
- pipeline_assetATTO-2306
Candidate in IND-enabling studies targeting atopic dermatitis.
- pipeline_assetATTO-1091
Candidate in IND-enabling studies targeting inflammatory bowel disease.
